CN115052593A - 包含绿茶提取物的组合物和功能性食品产品 - Google Patents
包含绿茶提取物的组合物和功能性食品产品 Download PDFInfo
- Publication number
- CN115052593A CN115052593A CN202180013027.2A CN202180013027A CN115052593A CN 115052593 A CN115052593 A CN 115052593A CN 202180013027 A CN202180013027 A CN 202180013027A CN 115052593 A CN115052593 A CN 115052593A
- Authority
- CN
- China
- Prior art keywords
- green tea
- extract
- citrus
- effect
- ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000020688 green tea extract Nutrition 0.000 title claims abstract description 65
- 229940094952 green tea extract Drugs 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims description 45
- 235000013376 functional food Nutrition 0.000 title claims description 17
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims abstract description 81
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims abstract description 78
- 235000020971 citrus fruits Nutrition 0.000 claims abstract description 70
- 229940030275 epigallocatechin gallate Drugs 0.000 claims abstract description 66
- 239000000284 extract Substances 0.000 claims abstract description 57
- 229930003949 flavanone Natural products 0.000 claims abstract description 45
- 235000011981 flavanones Nutrition 0.000 claims abstract description 45
- -1 flavanone glycoside Chemical class 0.000 claims abstract description 44
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 claims abstract description 39
- 229930182470 glycoside Natural products 0.000 claims abstract description 39
- 241000207199 Citrus Species 0.000 claims abstract description 35
- HDOMLWFFJSLFBI-UHFFFAOYSA-N Eriocitrin Natural products CC1OC(OCC2OC(Oc3cc(O)c4C(=O)CC(Oc4c3)c5ccc(OC6OC(COC7OC(C)C(O)C(O)C7O)C(O)C(O)C6O)c(O)c5)C(O)C(O)C2O)C(O)C(O)C1O HDOMLWFFJSLFBI-UHFFFAOYSA-N 0.000 claims abstract description 25
- OMQADRGFMLGFJF-MNPJBKLOSA-N Eriodictioside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=C(O)C(O)=CC=2)O1 OMQADRGFMLGFJF-MNPJBKLOSA-N 0.000 claims abstract description 25
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical class C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 12
- 230000000694 effects Effects 0.000 abstract description 64
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 abstract description 20
- 235000005487 catechin Nutrition 0.000 abstract description 20
- 150000001765 catechin Chemical class 0.000 abstract description 12
- 244000269722 Thea sinensis Species 0.000 description 32
- 241001672694 Citrus reticulata Species 0.000 description 21
- 230000001093 anti-cancer Effects 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 235000013305 food Nutrition 0.000 description 14
- 201000000585 muscular atrophy Diseases 0.000 description 13
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 12
- 235000006468 Thea sinensis Nutrition 0.000 description 12
- 230000003110 anti-inflammatory effect Effects 0.000 description 12
- 235000009569 green tea Nutrition 0.000 description 12
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 11
- 208000007536 Thrombosis Diseases 0.000 description 11
- 230000003579 anti-obesity Effects 0.000 description 11
- 206010008118 cerebral infarction Diseases 0.000 description 11
- 208000026106 cerebrovascular disease Diseases 0.000 description 11
- 229950001002 cianidanol Drugs 0.000 description 11
- 230000003308 immunostimulating effect Effects 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 9
- 235000013616 tea Nutrition 0.000 description 9
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000003623 enhancer Substances 0.000 description 8
- SBHXYTNGIZCORC-ZDUSSCGKSA-N eriodictyol Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-ZDUSSCGKSA-N 0.000 description 8
- TUJPOVKMHCLXEL-UHFFFAOYSA-N eriodictyol Natural products C1C(=O)C2=CC(O)=CC(O)=C2OC1C1=CC=C(O)C(O)=C1 TUJPOVKMHCLXEL-UHFFFAOYSA-N 0.000 description 8
- 235000011797 eriodictyol Nutrition 0.000 description 8
- SBHXYTNGIZCORC-UHFFFAOYSA-N eriodyctiol Natural products O1C2=CC(O)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-UHFFFAOYSA-N 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 8
- 230000002708 enhancing effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000003405 preventing effect Effects 0.000 description 7
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 6
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 150000002208 flavanones Chemical class 0.000 description 6
- 229940068517 fruit extracts Drugs 0.000 description 6
- 239000003495 polar organic solvent Substances 0.000 description 6
- 235000013824 polyphenols Nutrition 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 230000002785 anti-thrombosis Effects 0.000 description 4
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 description 4
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000007625 naringenin Nutrition 0.000 description 4
- 229940117954 naringenin Drugs 0.000 description 4
- 235000012149 noodles Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- WMBWREPUVVBILR-GHTZIAJQSA-N (+)-gallocatechin gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-GHTZIAJQSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 240000000560 Citrus x paradisi Species 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 102000002297 Laminin Receptors Human genes 0.000 description 3
- 108010000851 Laminin Receptors Proteins 0.000 description 3
- 206010028289 Muscle atrophy Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 3
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 3
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 3
- 235000010209 hesperetin Nutrition 0.000 description 3
- 229960001587 hesperetin Drugs 0.000 description 3
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 3
- 229940025878 hesperidin Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 201000006938 muscular dystrophy Diseases 0.000 description 3
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 2
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 2
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 2
- HMUJXQRRKBLVOO-AWEZNQCLSA-N 4'-methoxy-5,7-dihydroxyflavanone Chemical compound C1=CC(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 HMUJXQRRKBLVOO-AWEZNQCLSA-N 0.000 description 2
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 2
- 244000276331 Citrus maxima Species 0.000 description 2
- 235000001759 Citrus maxima Nutrition 0.000 description 2
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 2
- 240000003553 Leptospermum scoparium Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 102000015080 Protein Kinase C-delta Human genes 0.000 description 2
- 108010039230 Protein Kinase C-delta Proteins 0.000 description 2
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 2
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 2
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 239000003529 anticholesteremic agent Substances 0.000 description 2
- 229940127226 anticholesterol agent Drugs 0.000 description 2
- 229940125710 antiobesity agent Drugs 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 2
- 235000012734 epicatechin Nutrition 0.000 description 2
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 235000008960 ketchup Nutrition 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000000622 liquid--liquid extraction Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000013227 male C57BL/6J mice Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 2
- 229930019673 naringin Natural products 0.000 description 2
- 229940052490 naringin Drugs 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000001151 other effect Effects 0.000 description 2
- 238000004810 partition chromatography Methods 0.000 description 2
- 235000015927 pasta Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- DJOJDHGQRNZXQQ-AWEZNQCLSA-N sakuranetin Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)OC)=CC=C(O)C=C1 DJOJDHGQRNZXQQ-AWEZNQCLSA-N 0.000 description 2
- RNAPFFYGJWALAQ-UHFFFAOYSA-N sakuranetin Natural products O1C2=CC(C)=CC(O)=C2C(=O)CC1C1=CC=C(O)C=C1 RNAPFFYGJWALAQ-UHFFFAOYSA-N 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- DSAJORLEPQBKDA-AWEZNQCLSA-N sterubin Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)OC)=CC=C(O)C(O)=C1 DSAJORLEPQBKDA-AWEZNQCLSA-N 0.000 description 2
- DSAJORLEPQBKDA-UHFFFAOYSA-N sterubin Natural products O1C2=CC(OC)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 DSAJORLEPQBKDA-UHFFFAOYSA-N 0.000 description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- LSHVYAFMTMFKBA-PZJWPPBQSA-N (+)-catechin-3-O-gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-PZJWPPBQSA-N 0.000 description 1
- WVRDOLPMKOCJRJ-DENIHFKCSA-N (-)-Epigallocatechin 3-(3-methyl-gallate) Chemical compound OC1=C(O)C(OC)=CC(C(=O)O[C@H]2[C@H](OC3=CC(O)=CC(O)=C3C2)C=2C=C(O)C(O)=C(O)C=2)=C1 WVRDOLPMKOCJRJ-DENIHFKCSA-N 0.000 description 1
- BMJHAAZDURGGSC-TZIWHRDSSA-N (-)-Epigallocatechin 3-(4-methyl-gallate) Chemical compound C1=C(O)C(OC)=C(O)C=C1C(=O)O[C@H]1[C@@H](C=2C=C(O)C(O)=C(O)C=2)OC2=CC(O)=CC(O)=C2C1 BMJHAAZDURGGSC-TZIWHRDSSA-N 0.000 description 1
- NLAWPKPYBMEWIR-SKYQDXIQSA-N (2S)-poncirin Chemical compound C1=CC(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 NLAWPKPYBMEWIR-SKYQDXIQSA-N 0.000 description 1
- 108050007366 40S ribosomal protein SA Proteins 0.000 description 1
- 102100027271 40S ribosomal protein SA Human genes 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000612703 Augusta Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 235000008744 Brassica perviridis Nutrition 0.000 description 1
- 241000712024 Brassica rapa var. perviridis Species 0.000 description 1
- 241001062822 Camellia taliensis Species 0.000 description 1
- 240000004542 Capparis mitchellii Species 0.000 description 1
- RTIXKCRFFJGDFG-UHFFFAOYSA-N Chrysin Natural products C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 241000054078 Citrus depressa Species 0.000 description 1
- 241001337999 Citrus iyo Species 0.000 description 1
- 241000951471 Citrus junos Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000158474 Citrus sphaerocarpa Species 0.000 description 1
- 240000008701 Citrus sudachi Species 0.000 description 1
- 235000017727 Citrus sudachi Nutrition 0.000 description 1
- 241001522083 Citrus trifoliata Species 0.000 description 1
- 241000555678 Citrus unshiu Species 0.000 description 1
- 241000333459 Citrus x tangelo Species 0.000 description 1
- 240000009186 Citrus yuko Species 0.000 description 1
- 235000009136 Citrus yuko Nutrition 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- BXDRTHBTGNNTEW-NHCUHLMSSA-N Epicatechin 3-O-(4-methylgallate) Chemical compound C1=C(O)C(OC)=C(O)C=C1C(=O)O[C@H]1[C@@H](C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1 BXDRTHBTGNNTEW-NHCUHLMSSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- LUCQSVLCPJUJRN-UHVRHXOTSA-N Naringerin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O1)c1cc(O)c2C(=O)C[C@H](c3ccc(O)cc3)Oc2c1 LUCQSVLCPJUJRN-UHVRHXOTSA-N 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 241001455233 Obelia Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- FGUBFGWYEYFGRK-HNNXBMFYSA-N Pinocembrin Natural products Cc1cc(C)c2C(=O)C[C@H](Oc2c1)c3ccccc3 FGUBFGWYEYFGRK-HNNXBMFYSA-N 0.000 description 1
- 229930184207 Polyphenon Natural products 0.000 description 1
- NLAWPKPYBMEWIR-VGQRFNKBSA-N Poncirin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1Oc1cc(O)c2C(=O)C[C@@H](c3ccc(OC)cc3)Oc2c1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 NLAWPKPYBMEWIR-VGQRFNKBSA-N 0.000 description 1
- 235000000404 Poncirus trifoliata Nutrition 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000002555 anti-neurodegenerative effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- XGTBMCGGGJLOPS-IFMALSPDSA-N epicatechin 3-O-(3'-O-methylgallate) Chemical compound OC1=C(O)C(OC)=CC(C(=O)O[C@H]2[C@H](OC3=CC(O)=CC(O)=C3C2)C=2C=C(O)C(O)=CC=2)=C1 XGTBMCGGGJLOPS-IFMALSPDSA-N 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002207 flavanone derivatives Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- FTODBIPDTXRIGS-ZDUSSCGKSA-N homoeriodictyol Chemical compound C1=C(O)C(OC)=CC([C@H]2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-ZDUSSCGKSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000020888 liquid diet Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- URFCJEUYXNAHFI-ZDUSSCGKSA-N pinocembrin Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=CC=C1 URFCJEUYXNAHFI-ZDUSSCGKSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- BPJYAXCTOHRFDQ-UHFFFAOYSA-L tetracopper;2,4,6-trioxido-1,3,5,2,4,6-trioxatriarsinane;diacetate Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].CC([O-])=O.CC([O-])=O.[O-][As]1O[As]([O-])O[As]([O-])O1.[O-][As]1O[As]([O-])O[As]([O-])O1 BPJYAXCTOHRFDQ-UHFFFAOYSA-L 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Tea And Coffee (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
Abstract
本发明旨在以最有效的方式增强绿茶提取物如儿茶素的各种效果。所述绿茶提取物中所含的表没食子儿茶素没食子酸酯(A)与柑橘类提取物中所含的黄烷酮糖苷(B)的比(B/A)为0.2<B/A<1.6,或表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的圣草次苷(C)的比(C/A)为0.2<C/A<0.5。
Description
技术领域
本发明涉及包含儿茶素等绿茶提取物和柑橘类水果提取物或黄烷酮糖苷的组合物、功能性食品等。
背景技术
近年来,癌症占日本死亡人数的三分之一,因此迫切需要建立针对癌症治疗的适当治疗手段。在多发性骨髓瘤中,现在通过引进来那度胺和硼替佐米(即蛋白酶体的特异性抑制剂)改善了治疗环境。另一方面,很多病例是癌细胞对现有药物产生抗性,从而导致复发。为此,需要开发具有与常规药物不同的作用机制的抗癌剂。此外,这样的抗癌剂与现有疗法如果它们的剂量限制性毒性(DLT)不同,就可以联合使用,这使得能够制定更有效的治疗策略。
EGCG(表没食子儿茶素没食子酸酯、表没食子儿茶素-O-没食子酸酯)是绿茶中所含的主要儿茶素之一,据报道具有抗癌效果(非专利文献1),并已在患有慢性淋巴细胞白血病—一种血液癌症—的患者中进行了II期临床试验(非专利文献2)。虽然已知EGCG通过与细胞膜上的其靶分子67-kDa层粘连蛋白受体(67LR)结合而发挥抗癌效果,但EGCG对白血病细胞或多发性骨髓瘤细胞的致死效果有限(非专利文献2)。因此,强烈需要在EGCG用作抗癌剂时增强其效果。
专利文献1公开了,柑橘类水果提取物或黄烷酮糖苷增强儿茶素的抗癌效果和其它效果,包含儿茶素等绿茶提取物与柑橘类水果提取物或黄烷酮糖苷的组合物具有多种效果,例如抗癌效果、抗肌萎缩效果和抗肥胖效果。
引文列表
专利文献
专利文献1:WO2015/199169
非专利文献
非专利文献1:Khan N、Afaq F、Saleem M等,绿茶多酚(-)-表没食子儿茶素-3-没食子酸酯靶向多种信号通路(Targeting multiple signaling pathways by green teapolyphenol(-)-epigallocatechin-3-gallate),癌症研究(Cancer.res.),2006;66:2500-2505
非专利文献2:Shanafelt TD、Call TG、和Zent CS等,无症状Rai0至II期慢性淋巴细胞白血病患者每日口服Polyphenon E的I期试验(Phase I trial of daily oralPolyphenon E in patients with asymptomatic Rai stage 0 to II chroniclymphocytic leukemia),临床肿瘤学杂志(J.Clin.Oncol.),2009;27:3808-3814
发明内容
技术问题
虽然专利文献1提出了柑橘类水果提取物或黄烷酮糖苷会增强儿茶素等绿茶提取物的各种效果,但增强的程度不足。因此,本发明的目的在于提供能够以最有效的方式增强儿茶素等绿茶提取物的各种效果、包括抗癌效果的组合物和功能性食品。
问题解决方案
为了解决上述问题,本发明人进行了集中研究。结果他们发现,通过将儿茶素等绿茶提取物与柑橘类水果提取物或黄烷酮糖苷以给定的比混合,将以显著的程度增强儿茶素等绿茶提取物的各种效果。这导致了本发明的完成。
本发明包括以下内容。
(1)一种含绿茶提取物的组合物,包含绿茶提取物和柑橘类水果提取物,其中所述绿茶提取物中所含的表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的黄烷酮糖苷(B)的比(B/A)为0.2<B/A<1.6,或表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的圣草次苷(C)的比(C/A)为0.2<C/A<0.5。
(2)根据(1)所述的含绿茶提取物的组合物,其中所述比(B/A)为0.4≦B/A≦0.8。
(3)根据(1)所述的含绿茶提取物的组合物,其中所述比(C/A)为0.25≦C/A≦0.34。
(4)根据(1)所述的含绿茶提取物的组合物,其中所述黄烷酮糖苷是转糖基化橙皮苷。
(5)一种包含绿茶提取物和柑橘类水果提取物的功能性食品,其中所述绿茶提取物中所含的表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的黄烷酮糖苷(B)的比(B/A)为0.2<B/A<1.6,或表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的圣草次苷(C)的比(C/A)为0.2<C/A<0.5。
(6)根据(5)所述的功能性食品,其中所述比(B/A)为0.4≦B/A≦0.8。
(7)根据(5)所述的功能性食品,其中所述比(C/A)为0.25≦C/A≦0.34。
(8)根据(5)所述的功能性食品,其中所述黄烷酮糖苷是转糖基化橙皮苷。
本发明还涉及一种药剂,选自由抗癌剂、抗肌肉萎缩剂、抗肥胖剂、抗炎剂、降胆固醇剂、血栓形成或脑梗塞的预防剂、以及免疫刺激剂组成的组,所述药剂包含绿茶提取物和柑橘类水果提取物,其中所述绿茶提取物中所含的表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的黄烷酮糖苷(B)的比(B/A)为0.2<B/A<1.6,或表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的圣草次苷(C)的比(C/A)为0.2<C/A<0.5。
另外,本发明涉及一种增强剂,增强绿茶提取物或儿茶素的至少一种效果,所述效果选自由抗癌效果、抗肌萎缩效果、抗肥胖效果、抗炎效果、降胆固醇效果、血栓形成或脑梗塞的预防效果、和免疫刺激效果组成的组,所述增强剂包含绿茶提取物和柑橘类水果提取物,其中所述绿茶提取物中所含的表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的黄烷酮糖苷(B)的比(B/A)为0.2<B/A<1.6,或表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的圣草次苷(C)的比(C/A)为0.2<C/A<0.5。
此外,本发明涉及一种将包含绿茶提取物和柑橘类水果提取物的组合物施用于对象从而增强所述绿茶提取物或儿茶素在所述对象中的至少一种效果的方法,所述组合物中所述绿茶提取物中所含的表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的黄烷酮糖苷(B)的比(B/A)为0.2<B/A<1.6,或表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的圣草次苷(C)的比(C/A)为0.2<C/A<0.5,所述效果选自由抗癌效果、抗肌萎缩效果、抗肥胖效果、抗炎效果、降胆固醇效果、血栓形成或脑梗塞的预防效果、和免疫刺激效果组成的组(优选地,条件是排除对人类的医疗实践)。
在本发明中,所述绿茶提取物可以是选自由表儿茶素、表没食子儿茶素、表儿茶素没食子酸酯、没食子儿茶素没食子酸酯、表没食子儿茶素没食子酸酯和甲基化儿茶素组成的组中的至少一种儿茶素。
在本发明中,柑橘类水果提取物的例子包括黄烷酮糖苷、圣草酚和柚皮素。黄烷酮糖苷的例子是转糖基化橙皮苷。
在本发明的一个优选实施方式中,绿茶提取物是没食子儿茶素没食子酸酯、表没食子儿茶素没食子酸酯或甲基化儿茶素,柑橘类水果提取物是圣草酚。
本发明的组合物、食品、药剂和增强剂具有选自由抗癌效果、抗肌萎缩效果、抗肥胖效果、抗炎效果、降胆固醇效果、血栓形成或脑梗塞的预防效果和免疫刺激效果组成的组中的至少一种效果。
发明的有益效果
在本发明的组合物和功能性食品中,所述绿茶提取物中的表没食子儿茶素没食子酸酯与所述柑橘类水果提取物中的黄烷酮糖苷的比在给定范围内,或者表没食子儿茶素没食子酸酯与圣草次苷的比在给定范围内。由此,以显著的程度增强了表没食子儿茶素没食子酸酯的各种效果。这使得本发明的组合物和功能性食品能够发挥优异的抗癌效果和其它效果。
附图说明
[图1]图1是显示施用各种组合物后血浆cGMP浓度测量结果的特性图。
[图2]图2是显示施用各种组合物后血浆cGMP浓度测量结果的特性图。
[图3]图3是显示施用各种组合物后血浆cGMP浓度测量结果的特性图。
具体实施方式
以下将详细地描述本发明。
本发明的组合物和功能性食品各自包含绿茶提取物和柑橘类水果提取物,其中所述绿茶提取物中所含的表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的黄烷酮糖苷(B)的比(B/A)为0.2<B/A<1.6,或表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的圣草次苷(C)的比(C/A)为0.2<C/A<0.5。
如WO2015/199169中所公开的,包含作为多酚之一的圣草酚等的柑橘类水果提取物具有增强绿茶提取物、例如表没食子儿茶素没食子酸酯(表没食子儿茶素-O-没食子酸酯(EGCG))的各种效果、包括抗癌效果的作用。绿茶提取物的效果的例子包括抗肥胖效果、抗炎效果、降胆固醇效果、抗血栓形成效果、免疫刺激效果和抗肌萎缩效果(WO2015/199169)。据报道,绿茶提取物具有抗癌效果、抗胰岛素抵抗效果、抗炎效果、抗过敏效果、抗肌萎缩效果、动脉硬化预防效果、抗血栓形成效果、阿尔茨海默氏病(Alzheimer's disease)预防效果。
WO2015/199169的描述如下。即,使用(a1)圣草酚或其结构类似物,即柚皮苷或橙皮苷;(a2)这些多酚的糖苷,其可在体内代谢成为这些多酚;或(a3)含有(a1)或(a2)的食品,将它们与下列进行组合:(b1)EGCG;(b2)甲基化EGCG,如同在EGCG的情况下一样,甲基化EGCG也充当67LR激动剂;或(b3)含有(b1)或(b2)的食品,发挥抗癌效果、抗肌萎缩效果、抗肥胖效果、抗胰岛素抵抗效果、抗炎效果、抗过敏效果、动脉硬化预防效果、抗血栓形成效果、抗神经变性效果和抗炎效果。因此,在(a1)、(a2)或(a3)与(b1)、(b2)或(b3)之间的上述组合可用作食品、药物或补充剂,旨在通过如上所述的效果预防或治疗疾病,如血栓性疾病(例如,肺栓塞、DIC、心肌梗塞或脑梗塞)、癌症、肌萎缩、肥胖、胰岛素抵抗疾病、炎性疾病(例如肖格伦氏病和胶原病)、过敏性疾病、动脉硬化和神经变性疾病(例如,脑部疾病,如阿尔茨海默氏病和痴呆)。
(1)绿茶提取物
所述绿茶提取物由山茶科常绿树——茶树制备,这样的提取物至少含有表没食子儿茶素没食子酸酯。绿茶树的例子包括茶树,例如大理山茶(Camellia taliensis)和中华山茶(Camellia sinensis)。可以使用的绿茶品种的例子包括:茶树(Camellia sinensis(L.)Kuntze)、阿萨姆(Assam)茶树(Camellia sinensis(L.)Kuntze var assamica(J.W.Mast)Kitam.)、中华山茶和大理山茶之间的杂交种、茶品种“薮北(Yabukita)”、“红富贵(Benifuuki)”、“红藤(Benifuji)”、“红誉(Benihomare)”、“八重穗(Yaeho)”、“Surugawase”、“丰绿(Yutakamidori)”、“金谷绿(Kanayamidori)”、“奥武藏(Okumusashi)”、“Seisindaipan”、“青心乌龙(Seisin oolong)”、“大叶乌龙(Ohbaoolong)”、“红花(Benibana)”、“红光(Benihikari)”、“山峡(Yamakai)”、“山绿(Yamamidori)”、“唐红(Karabeni)”、“香骏(Koushun)”、“苍风(Soufuu)”、“福绿(Fukumidori)”、“峰香(Minekaori)”、“红光(Benihikari)”、“南香(Minamikaori)”、“和泉(Izumi)”、“富春(Fuushun)”、“玉绿(Tamamidori)”、“Kuritawase”、“春明(Shunmei)”、“狭山绿(Sayamamidori)”、“朝雾(Asagiri)”、“北名(Hokumei)”、“多田锦(Tadanishiki)”、“朝日(Asahi)”、“狭山香(Sayamakaori)”、“茗绿(Meiryoku)”、“大和绿(Yamatomidori)”、“朝露(Asatsuyu)”、“Toyoka”、“夏绿(Natsumidori)”、“宇治光(Ujihikari)”、“大井早生(Ooiwase)”、“Gokoh”、“Inzatsu 131”、“牧之原早生(Makinoharawase)”、“高千穗(Takachiho)”、“驹影(Komakage)”、“早绿(Samidori)”、“驹影(Komakage)”、“初红叶(Hatsumomiji)”、“凉风(Ryoufuu)”、“Minamisayaka”、“Saemidori”、“奥丰(Okuyutaka)”、“富士绿(Fujimidori)”、“Sunrouge”和“奥绿(Okumidori)”。其中,“薮北(Yabukita)”、“红富贵(Benifuuki)”、“金谷绿(Kanayamidori)”、“奥武藏(Okumusashi)”、“苍风(Soufuu)”、“富春(Fuushun)”、“多田锦(Tadanishiki)”和“Sunrouge”是更为优选的。另外,来自这些茶树的茶叶的例子包括绿茶、精制绿茶、粗茶、嫩枝绿茶、芽绿茶、糙米绿茶、碎绿茶、粉末绿茶、煎茶(parched green tea)、中国甜茶、包种茶、乌龙茶和红茶。
虽然对提取溶剂没有特别限制,但可使用水、有机溶剂、或水和有机溶剂的混合物。
有机溶剂的例子包括极性有机溶剂,如含有1至4个碳原子的低级醇(例如甲醇、乙醇、丙醇、异丙醇、正丁醇、异丁醇、仲丁醇和叔丁醇)和酮(例如二甲基酮、甲基乙基酮、丙酮和甲基异丁基酮),和非极性有机溶剂,如乙酸甲酯、乙酸乙酯、乙酸丁酯和乙醚。也可以将这些极性有机溶剂中的任意种与这些非极性有机溶剂中的任意种适当组合使用。热水、乙醇和含水乙醇是优选的。含水醇中的醇浓度为30体积/体积%至90体积/体积%,优选为40体积/体积%至70体积/体积%。在热水的情况下,它的温度是40摄氏度至100摄氏度,优选60摄氏度至100摄氏度。
用于获得绿茶提取物的提取技术的例子包括常规技术,如浸渍提取、加热提取、连续提取和超临界提取。由此获得的绿茶提取物然后可依照常规技术进行浓缩。所得到的绿茶提取物、浓缩物等可依照常规技术进一步纯化。纯化技术的例子包括超滤、用吸附树脂处理、分子色谱、分配色谱和液-液提取。
干燥技术的例子包括但不限于喷雾干燥和冷冻干燥。除了表没食子儿茶素没食子酸酯之外,绿茶提取物还可含有多酚类、儿茶素类等。绿茶提取物优选含有儿茶素、表儿茶素、表没食子儿茶素、儿茶素没食子酸酯、表儿茶素没食子酸酯、没食子儿茶素没食子酸酯、甲基化儿茶素等。
本发明中所指的甲基化儿茶素的主要成员优选包括:表没食子儿茶素-3-O-(3-O-甲基)没食子酸酯(以下称为“EGCG 3”Me”)、表儿茶素-3-O-(3-O-甲基)没食子酸酯(以下称为“ECG 3”Me”)、表儿茶素-3-O-(4-O-甲基)没食子酸酯(以下称为“ECG 4”Me”)、表没食子儿茶素-3-O-(4-O-甲基)没食子酸酯(以下称为“EGCG 4”Me”)、没食子儿茶素-3-O-(3-O-甲基)没食子酸酯(以下称为“GCG 3”Me”)、儿茶素-3-O-(3-O-甲基)没食子酸酯(以下称为“CG3”Me”)、儿茶素-3-O-(4-O-甲基)没食子酸酯(以下称为“CG 4”Me”)、或没食子儿茶素-3-O-(4-O-甲基)没食子酸酯(以下称为“GCG 4”Me”)、及其异构化产物。
所述组合物中绿茶提取物的含量将取决于所述组合物的剂型或其施用方式而异,但可考虑后述的柑橘类水果提取物的含量来适当确定。此外,在本发明中,所述组合物可包含与绿茶提取物中所含的儿茶素不同的其它儿茶素。其例子是合成儿茶素。合成儿茶素类可按照常规技术获得(亚洲化学杂志(Chem.Asian J.)2010,5,2231-2248.DOI:10.1002/亚洲.201000372)。
也可使用可商购的绿茶提取物。可以使用的可商购绿茶提取物的例子是由三井农林公司制造的Polyphenon(注册商标)。
(2)柑橘类水果提取物
柑橘类水果提取物是从柑橘类水果中提取的产物,至少含有圣草次苷或黄烷酮糖苷。柑橘类水果的例子包括以下例子。
柑橘属的例子包括橙、葡萄柚、香橙(Citrus junos)、苦橙、臭橙(Citrussphaerocarpa)、酢橘(Citrus sudachi)、柚柑(Citrus yuko hort.ex Tanaka)、Yukou(一种日本本土柑橘)、扁平橘(Citrus depressa)、柠檬、酸橙、夏橙(Citrus natsudaidai)、八朔蜜柑(Citrus hassaku)、伊予柑(Citrus iyo)、柚子(Citrus grandis)、蜜橘(mandarinorange)、温州蜜柑(satsuma mandarin)、椪柑(Cirus reticulata)、立花橘(Citrustachibana)、纪州蜜柑(Citrus kinokuni)、伏令夏橙(Valencia orange)、脐橙、红橙、雅法橙(Jaffa orange)、香柠檬(bergamot orange)和奇诺托桔(Chinotto orange)。
除上述柑橘属的柑橘类水果外,还可使用枳、金橘等。
作为用于提取柑橘类水果的提取溶剂,与上述同样地,可使用水、有机溶剂、或水和有机溶剂的混合物。有机溶剂的例子包括极性有机溶剂,如含有1至4个碳原子的低级醇(例如甲醇、乙醇、丙醇、异丙醇、正丁醇、异丁醇、仲丁醇和叔丁醇)和酮(例如二甲基酮、甲基乙基酮、丙酮和甲基异丁基酮),和非极性有机溶剂,如乙酸甲酯、乙酸乙酯、乙酸丁酯和乙醚。水或乙醇是优选的。也可以将这些极性有机溶剂中的任意种与这些非极性有机溶剂中的任意种适当组合使用。
用于获得柑橘类水果提取物的提取技术的例子包括常规技术,如浸渍提取、加热提取、连续提取和超临界提取。然后可以将提取物依照常规技术进行浓缩。所得到的柑橘类水果提取物、浓缩物等可依照常规技术进一步纯化。纯化技术的例子包括超滤、用吸附树脂处理、分子色谱、分配色谱和液-液提取。
柑橘类水果提取物至少含有圣草次苷或黄烷酮糖苷。黄烷酮糖苷的例子包括但不特别限于橙皮苷、柚皮苷、枸橘苷和樱花苷。除了圣草次苷或黄烷酮糖苷之外,柑橘类水果提取物还可含有黄烷酮类,如丁炔、圣草酚、橙皮素、高圣草酚、异樱花素、柚皮素、松属素、樱花素或7-O-甲基圣草酚(sterubin)。
所述组合物可包含与柑橘类水果提取物中所含的黄烷酮或黄烷酮糖苷不同的其它黄烷酮或黄烷酮糖苷。例子包括合成黄烷酮和黄烷酮的转糖基化化合物,后者包含与黄烷酮结合的糖分子,例如转糖基化橙皮苷。具体的例子包括合成圣草酚、合成柚皮素和合成橙皮素,它们可以单独使用或以两种以上的组合使用。合成圣草酚、合成柚皮素和合成橙皮素可依照常规技术获得(欧洲有机化学杂志(European J.Org.Chem.),2012(3):449-462,doi:10.1002/ejoc.201101228)。可以使用的转糖基化橙皮苷的例子是可得自Hayashibara公司和Glico Nutrition公司的转糖基化橙皮苷。
(3)组合物
在本发明组合物中,所述绿茶提取物中所含的表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的黄烷酮糖苷(B)的比(B/A)为0.2<B/A<1.6,或表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的圣草次苷(C)的比(C/A)为0.2<C/A<0.5。特别地,所述比(B/A)优选为0.4≦B/A≦0.8,更优选为0.5≦B/A≦0.7。所述比(C/A)优选为0.25≦C/A≦0.34,更优选为C/A=0.3。
通过维持上述比,可以以显著的程度增强表没食子儿茶素没食子酸酯的各种效果,例如抗癌效果。表没食子儿茶素没食子酸酯的各种效果可以基于环磷酸鸟苷(cGMP)的产生量来确定。已经发现,表没食子儿茶素没食子酸酯通过67LR激活内皮NO合酶(eNOS)以诱导NO产生,然后以可溶性鸟苷酸环化酶(sGC)依赖性方式加速cGMP产生。另外,已发现cGMP激活蛋白激酶C-δ(PKC-δ)和酸性鞘磷脂酶(ASM)。具体而言,cGMP与表没食子儿茶素没食子酸酯诱导癌细胞凋亡的信号通路关联,并且cGMP充当表没食子儿茶素没食子酸酯的各种效果的生物标志物。
除了上述成分之外,所述组合物还可包含容许用于食品中的载体以及其它已知或公知的添加剂。添加剂的例子包括药物或食品中常用的那些,如赋形剂、粘合剂、润滑剂、崩解剂、着色剂、矫味剂、乳化剂、表面活性剂、增溶剂、悬浮剂、等渗剂、缓冲剂、防腐剂、抗氧化剂、稳定剂、和促吸收剂,它们可根据需要以适当的组合使用。
所述组合物可以是液体、固体、粉末和凝胶中的任何形式,并且所述组合物可配制成任何口服剂型,如片剂、粉剂、胶囊(硬胶囊或软胶囊)、颗粒剂、丸剂、溶液、或糖浆。这些制剂可以依照常规技术制备。当组合物呈溶液形式时,可以优选使用水和其它水性介质作为载体。
当组合物为固体形式时,要添加的成分包括赋形剂,如结晶纤维素、硬脂酸镁和硬脂酸钙,以及膨化剂,如玉米淀粉和藻酸。
配制成粉末、固体或溶液剂型所需的化合物的例子包括赤藓糖醇、麦芽糖醇、羟丙基纤维素、高岭土和滑石粉。
所述组合物具有选自由抗癌效果、抗肌萎缩效果、抗肥胖效果、抗炎效果、降胆固醇效果、血栓形成或脑梗塞的预防效果和免疫刺激效果组成的组中的至少一种效果。因此,上述组合物可以用作抗癌剂、抗肌萎缩剂、抗肥胖剂、抗炎剂、降胆固醇剂、血栓形成或脑梗塞的预防剂、或免疫刺激剂。上述各药剂中,制备茶提取物或儿茶素和柑橘类水果提取物或黄烷酮的方法以及这些各成分的含量如上所述。
摄取本发明组合物的对象的例子包括但不特别限于:人类,非人类哺乳动物如实验动物(例如小鼠、大鼠、豚鼠和兔子)、家畜(例如牛、马、猪和山羊)、以及宠物(例如狗、猫和其它宠物)。预期本发明的组合物能够预防或治疗癌症、肌萎缩(例如肌萎缩性侧索硬化(ALS))、炎性疾病、血栓形成或脑梗塞、高脂血症和感染,或改善生活方式相关的疾病和肥胖。
以表没食子儿茶素没食子酸酯的量计,每千克体重摄取本发明组合物的量优选为每天0.1至30mg,更优选0.1至20mg,进一步优选0.1至10mg,最优选0.1至5mg。在本发明的组合物中,表没食子儿茶素没食子酸酯(A)与黄烷酮糖苷(B)的比(B/A)、或表没食子儿茶素没食子酸酯(A)与圣草次苷(C)的比(C/A)在给定的范围内。因此,在如上所述的低剂量表没食子儿茶素没食子酸酯下,就能够充分发挥由表没食子儿茶素没食子酸酯实现的各种效果。
(4)食品
本发明的食品包含绿茶提取物和柑橘类水果提取物,其中所述绿茶提取物中所含的表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的黄烷酮糖苷(B)的比(B/A)为0.2<B/A<1.6,或表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的圣草次苷(C)的比(C/A)为0.2<C/A<0.5。由于所述食品以给定的比含有这样的成分,它特别可以用作功能性食品、补充剂等,旨在发挥选自由抗癌效果、抗肌萎缩效果、抗肥胖效果、抗炎效果、降胆固醇效果、血栓形成或脑梗塞的预防效果和免疫刺激效果组成的组中的至少一种效果。
本发明的食品(特别是功能性食品)可以是任何形式,例如补充剂(即粉剂、颗粒剂、软胶囊、硬胶囊、片剂、咀嚼片或速崩片)、饮料(例如茶饮料、碳酸饮料、乳酸饮料或运动饮料)、点心(例如口香糖、巧克力或饼干、糖果)、油、食用油脂产品(例如蛋黄酱、调味酱或黄油)、调味品(例如番茄酱或酱汁)、流质饮食、乳制品(例如牛奶、酸奶或奶酪)、烘焙品、或面条(例如白小麦面条、荞麦面条、中国面条、意大利面、Hiyamugi(日本细面)、或米粉)。应当注意,本发明的食品不限于这些形式。
摄取本发明组合物的对象的例子包括但不特别限于:人类,非人类哺乳动物如实验动物(例如小鼠、大鼠、豚鼠和兔子)、家畜(例如牛、马、猪和山羊)、以及宠物(例如狗、猫和其它宠物)。
以表没食子儿茶素没食子酸酯的量计,每千克体重的本发明食品摄取量优选为每天0.1至30mg,更优选0.1至20mg,进一步优选0.1至10mg,最优选0.1至5mg。在本发明的食品中,表没食子儿茶素没食子酸酯(A)与黄烷酮糖苷(B)的比(B/A)、或表没食子儿茶素没食子酸酯(A)与圣草次苷(C)的比(C/A)在给定的范围内。因此,在如上所述的低剂量表没食子儿茶素没食子酸酯下,就能够充分发挥由表没食子儿茶素没食子酸酯实现的各种效果。
(5)增强剂
所述增强剂包含绿茶提取物和柑橘类水果提取物,包含的方式使得所述绿茶提取物中所含的表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的黄烷酮糖苷(B)的比(B/A)为0.2<B/A<1.6,或表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的圣草次苷(C)的比(C/A)为0.2<C/A<0.5。由此增强了表没食子儿茶素没食子酸酯的各种效果,如抗癌效果、抗肥胖效果、抗炎效果、降胆固醇效果、抗血栓形成效果、免疫刺激效果、以及抗肌萎缩效果。在包含柑橘类水果提取物中的黄烷酮糖苷(B)或圣草次苷(C)的表没食子儿茶素没食子酸酯增强剂中,具体而言,黄烷酮糖苷(B)或圣草次苷(C)与表没食子儿茶素没食子酸酯(A)的比为0.2<B/A<1.6或0.2<C/A<0.5。换言之,所述表没食子儿茶素没食子酸酯增强剂增强了表没食子儿茶素没食子酸酯的选自由抗癌效果、抗肌萎缩效果、抗肥胖效果、抗炎效果、降胆固醇效果、血栓形成或脑梗塞的预防效果和免疫刺激效果组成的组中的至少一种效果。
对象摄取绿茶提取物和柑橘类水果提取物,摄取的方式使得所述绿茶提取物中所含的表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的黄烷酮糖苷(B)的比(B/A)成为0.2<B/A<1.6,或表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的圣草次苷(C)的比(C/A)成为0.2<C/A<0.5。由此,能够在所述对象中增强表没食子儿茶素没食子酸酯的选自由抗癌效果、抗肌萎缩效果、抗肥胖效果、抗炎效果、降胆固醇效果、血栓形成或脑梗塞的预防效果和免疫刺激效果组成的组中的至少一种效果。应该注意的是,可以排除对人类的医疗实践。
摄取所述增强剂或接受所述增强方法的对象的例子如上所述。其例子包括但不特别限于:人类,非人类哺乳动物如实验动物(例如小鼠、大鼠、豚鼠和兔子)、家畜(例如牛、马、猪和山羊)、以及宠物(例如狗、猫和其它宠物)。
使用本发明的增强剂时,每千克体重的表没食子儿茶素没食子酸酯摄取量可以为每天0.1至30mg,更优选0.1至20mg,进一步优选0.1至10mg,最优选0.1至5mg。在本发明的增强剂中,表没食子儿茶素没食子酸酯(A)与黄烷酮糖苷(B)的比(B/A)、或表没食子儿茶素没食子酸酯(A)与圣草次苷(C)的比(C/A)在给定的范围内。因此,在如上所述的低剂量表没食子儿茶素没食子酸酯下,就能够充分发挥由表没食子儿茶素没食子酸酯实现的各种效果。
实施例
下面,参照实施例更详细地描述本发明,但本发明的技术范围不限于以下实施例。
实施例1
施用例1
将EGCG(西格玛奥德里奇公司)和各种黄酮类化合物(圣草次苷:ALB Technology公司;转糖基化橙皮苷:Hayashibara公司;或圣草酚:EXTRASYNTHESE公司)溶于纯水中,并将所得到的溶液使用饲管经口施用于雄性C57BL/6J小鼠(6周龄,体重:25g,每组由3或6只小鼠组成(Kyudo公司)。
施用后120分钟,在异氟烷(添加EDTA;终浓度:1.5mg/ml)麻醉下通过主动脉放血处死小鼠。将收集的血液在4℃和200×g下离心15分钟以收集血浆样品。使用TR-FRET试剂盒(cisbio公司)和荧光读板器(EnVision(商标)Multilabel Reader,PerkinElmer公司)测量血浆样品中的cGMP浓度。使用Statcel 4.0(Excel管理软件),通过唐那氏(Dunnett’s)检验以5%的风险作为统计显著性点进行统计处理。
施用例2
将绿茶提取物(每克含EGCG 146mg)和转糖基化橙皮苷(α橙皮苷PA-T,GlicoNutrition公司)溶于纯水中,将所得到的溶液使用饲管经口施用于雄性C57BL/6J小鼠(6周龄,体重:25g,每组由5或6只小鼠组成)(Kyudo公司)。
施用后120分钟,在异氟烷(添加EDTA;终浓度:1.5mg/ml)麻醉下通过主动脉放血处死小鼠。将收集的血液在4℃和200×g下离心15分钟以收集血浆样品。使用TR-FRET试剂盒(cisbio公司)和荧光读板器(EnVision(商标)Multilabel Reader,PerkinElmer公司)测量血浆样品中的cGMP浓度。通过学生t检验以5%的风险作为统计显著性点进行统计处理。
结果
为了比较,按照施用例2中所述的方法,对一组小鼠仅施用所述绿茶提取物,并对各组小鼠施用不同水平的转糖基化橙皮苷。各组的cGMP浓度测量结果示于图1。施用例1和施用例2的实验结果分别示于图2和图3。图1至3中所示的施用量是基于千克小鼠体重的(施用于小鼠的量(mg/kg))。
表1显示了图1至图3中所示的实验结果的总结。在表1所示的指示结果的栏中,在图2和图3中表现出显著差异的试验组以圆圈指示。
如图1至3和表1所示,当所述绿茶提取物中所含的表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的黄烷酮糖苷(B)的比(B/A)为0.2<B/A<1.6,或表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的圣草次苷(C)的比(C/A)为0.2<C/A<0.5时,血浆cGMP浓度以显著的程度增加。结果表明,其中绿茶提取物中所含的表没食子儿茶素没食子酸酯(A)与柑橘类提取物中所含的黄烷酮糖苷(B)的比(B/A)为0.2<B/A<1.6、或表没食子儿茶素没食子酸酯(A)与柑橘类提取物中所含的圣草次苷(C)的比(C/A)为0.2<C/A<0.5的包含绿茶提取物和柑橘类水果提取物的组合物能够将表没食子儿茶素没食子酸酯的多种效果如抗癌效果以显著的程度增强。
Claims (8)
1.一种含绿茶提取物的组合物,包含绿茶提取物和柑橘类水果提取物,其中所述绿茶提取物中所含的表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的黄烷酮糖苷(B)的比(B/A)为0.2<B/A<1.6,或表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的圣草次苷(C)的比(C/A)为0.2<C/A<0.5。
2.根据权利要求1所述的含绿茶提取物的组合物,其中所述比(B/A)为0.4≦B/A≦0.8。
3.根据权利要求1所述的含绿茶提取物的组合物,其中所述比(C/A)为0.25≦C/A≦0.34。
4.根据权利要求1所述的含绿茶提取物的组合物,其中所述黄烷酮糖苷是转糖基化橙皮苷。
5.一种包含绿茶提取物和柑橘类水果提取物的功能性食品,其中所述绿茶提取物中所含的表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的黄烷酮糖苷(B)的比(B/A)为0.2<B/A<1.6,或表没食子儿茶素没食子酸酯(A)与所述柑橘类提取物中所含的圣草次苷(C)的比(C/A)为0.2<C/A<0.5。
6.根据权利要求5所述的功能性食品,其中所述比(B/A)为0.4≦B/A≦0.8。
7.根据权利要求5所述的功能性食品,其中所述比(C/A)为0.25≦C/A≦0.34。
8.根据权利要求5所述的功能性食品,其中所述黄烷酮糖苷是转糖基化橙皮苷。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-036833 | 2020-03-04 | ||
JP2020036833A JP7364497B2 (ja) | 2020-03-04 | 2020-03-04 | 緑茶抽出物含有組成物、機能性食品 |
PCT/JP2021/008183 WO2021177352A1 (en) | 2020-03-04 | 2021-03-03 | Composition and functional food product comprising green tea extract |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115052593A true CN115052593A (zh) | 2022-09-13 |
Family
ID=75143696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180013027.2A Pending CN115052593A (zh) | 2020-03-04 | 2021-03-03 | 包含绿茶提取物的组合物和功能性食品产品 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230092815A1 (zh) |
EP (1) | EP4114382A1 (zh) |
JP (1) | JP7364497B2 (zh) |
CN (1) | CN115052593A (zh) |
WO (1) | WO2021177352A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102379821B1 (ko) * | 2020-04-28 | 2022-03-30 | 한국핵융합에너지연구원 | 에피갈로카테킨 갈레이트 및 플로로글루시놀 혼합물에 플라즈마 처리하여 획득한 신규 화합물을 유효성분으로 함유하는 항비만용 조성물 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103648481A (zh) * | 2011-06-16 | 2014-03-19 | 株式会社爱茉莉太平洋 | 在植物细胞中保持稳定的活性物质及其制备方法 |
US20150079060A1 (en) * | 2007-08-31 | 2015-03-19 | Ford D. Albritton, IV | Nutritional supplement |
US20170156361A1 (en) * | 2014-06-27 | 2017-06-08 | Kyushu University, National University Corporation | Catechin function enhancement method |
CN110139568A (zh) * | 2016-11-16 | 2019-08-16 | 快乐糖果有限公司 | 用于血糖控制的加强糖的粗制剂的方法和组合物 |
CN110708965A (zh) * | 2017-06-01 | 2020-01-17 | 莫特迩公司 | 动物饲料添加剂 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6989161B2 (en) | 2000-06-12 | 2006-01-24 | Access Business Group International Llc | Phytonutrient nutritional supplement |
-
2020
- 2020-03-04 JP JP2020036833A patent/JP7364497B2/ja active Active
-
2021
- 2021-03-03 EP EP21713773.6A patent/EP4114382A1/en not_active Withdrawn
- 2021-03-03 CN CN202180013027.2A patent/CN115052593A/zh active Pending
- 2021-03-03 WO PCT/JP2021/008183 patent/WO2021177352A1/en unknown
- 2021-03-03 US US17/908,811 patent/US20230092815A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150079060A1 (en) * | 2007-08-31 | 2015-03-19 | Ford D. Albritton, IV | Nutritional supplement |
CN103648481A (zh) * | 2011-06-16 | 2014-03-19 | 株式会社爱茉莉太平洋 | 在植物细胞中保持稳定的活性物质及其制备方法 |
US20170156361A1 (en) * | 2014-06-27 | 2017-06-08 | Kyushu University, National University Corporation | Catechin function enhancement method |
CN110139568A (zh) * | 2016-11-16 | 2019-08-16 | 快乐糖果有限公司 | 用于血糖控制的加强糖的粗制剂的方法和组合物 |
CN110708965A (zh) * | 2017-06-01 | 2020-01-17 | 莫特迩公司 | 动物饲料添加剂 |
Also Published As
Publication number | Publication date |
---|---|
EP4114382A1 (en) | 2023-01-11 |
US20230092815A1 (en) | 2023-03-23 |
WO2021177352A1 (en) | 2021-09-10 |
JP7364497B2 (ja) | 2023-10-18 |
JP2021136906A (ja) | 2021-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101351674B1 (ko) | 폴리페놀을 함유하는 신규 조성물 | |
US10251408B2 (en) | Catechin function enhancement method | |
US20090312409A1 (en) | Lipopexia inhibitor and food or beverage | |
JP4997523B2 (ja) | 抗アレルギー剤及びこれを含有する飲食品、外用剤、化粧料 | |
JP2010070540A (ja) | Dgat阻害剤 | |
JP6046056B2 (ja) | 脱ラムノシルアクテオシド含有オリーブ抽出物 | |
CN115052593A (zh) | 包含绿茶提取物的组合物和功能性食品产品 | |
KR101917363B1 (ko) | 콩 발아배아 추출물을 포함하는 여성 갱년기 질환의 예방 또는 치료용 약학조성물 | |
JP2001064172A (ja) | Apc遺伝子の変異に起因する疾患の予防・治療剤 | |
JP6778506B2 (ja) | 機能性食品組成物 | |
JP2004313189A (ja) | カテキン含有飲食物及びその製造方法 | |
JP7242034B2 (ja) | フラボノール配糖体含有組成物 | |
JP5673207B2 (ja) | 新規レスベラトロール誘導体 | |
JP2022046159A (ja) | 抗ストレス用食品組成物 | |
JP2023008374A (ja) | 抗肥満剤用組成物、機能性食品 | |
JP2018078860A (ja) | 経口組成物 | |
CN110121269B (zh) | 用于肠细胞中的儿茶素摄取的增强剂 | |
JP2024048688A (ja) | 血中non-HDLコレステロール低下用若しくは上昇抑制用組成物 | |
EP3939603A1 (en) | Catechin enzyme-treated material having increased gallic acid, epicatechin and epigallocatechin contents, and method for preparing same | |
KR20180009316A (ko) | 3-O-갈로일-3,3',5,5',7-펜타하이드록시플라반(3-O-galloyl-3,3',5,5',7- pentahydroxyflavan)을 포함하는 인지 기능 개선용 조성물 | |
JP2022038319A (ja) | インターフェロン-γ産生促進剤 | |
KR20210026725A (ko) | 에피갈로카테킨갈레이트를 유효성분으로 포함하는 인지능력 개선용 조성물 | |
JP2021088537A (ja) | プラスミノゲンアクチベーターインヒビター−1産生抑制剤 | |
JP2019094306A (ja) | 血中中性脂肪低減作用及び肝臓中性脂肪低減作用を有する脂質代謝改善剤 | |
KR20110115442A (ko) | 정향을 유효성분으로 함유하는 숙취해소용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |